Start: May 2012
End: March 2014
The purpose of this study is to determine whether daily resveratrol therapy can delay or alter the deterioration of memory and daily functioning in people with probable Alzheimer's disease.
Minimum Age: 50 Years
Maximum Age: N/A
++Diagnosis of probable Alzheimer's disease (NINDS-ADRDA criteria)++Age 50 years or older++Able to ingest oral medications++Caregiver/Study Partner who has direct contact with the participant more than 2 days per week to accompany participant to all visits++MMSE score between 14 and 26 (inclusive)++Modified Hachinski score of less than or equal to 4++Able to abstain from ingesting large quantities of resveratrol-containing foods (including red wine); 1-2 glasses of red wine or red grape juice daily acceptable; 1 serving of red grapes daily acceptable++Able to abstain from ingesting herbal/natural preparations or dietary supplements containing resveratrol
++Non-Alzheimer's dementia or probable Alzheimer's disease with Down syndrome++History of clinically significant stroke++Current evidence or history in past 2 years of epilepsy, focal brain lesion, head injury with loss of consciousness, or any major psychiatric disorder++Sensory impairment that would preclude the participant from participating in or cooperating with the protocol++Use of investigational agent within 2 months prior to screening++Significant clinical disorder or laboratory finding that renders the participant unsuitable for receiving an investigational drug, including clinically significant or unstable hematologic, hepatic, cardiovascular, pulmonary, gastrointestinal, endocrine, metabolic, renal, or other systemic disease or laboratory abnormality++Active neoplastic disease, history of cancer within 5 years prior to screening (skin melanoma or stable prostate cancer is allowable)++History of seizure within past 5 years++Pregnancy or possible pregnancy
Contact study personnel listed either under the general study contact or the location nearest you.
Lead: Alzheimer's Disease Cooperative Study (ADCS)
Source: ClinicalTrials.gov ID: NCT01504854